Reference-grade research compound
Cagrilintide
Synthetic 37-residue long-acting amylin analog peptide, C-terminally amidated, with a C20 fatty diacid conjugated at the N-terminal lysine
Schematic — no PDB structure deposited
- Scientific name
- Synthetic 37-residue long-acting amylin analog peptide, C-terminally amidated, with a C20 fatty diacid conjugated at the N-terminal lysine
- Sequence
- —
- Length
- 37-mer
- Molecular formula
- C194H312N54O59S2
- Molecular weight
- 4409.07 g/mol
- Form
- lyophilized
- Available sizes
- 5 mg, 10 mg
- Storage
- Store lyophilized powder at −20 °C, desiccated and protected from light. Stable for 24 months.
- Batch HPLC purity
- 99.5%
Description
Synthetic 37-residue amylin analog peptide with a disulfide bridge, a C-terminal amide, and an N-terminally conjugated C20 fatty diacid side chain. Used in vitro as a reference compound in amylin and calcitonin receptor binding and cAMP accumulation assays in transfected cell-line model systems. Supplied as a lyophilized acetate salt.
Storage and stability
Store lyophilized powder at −20 °C, desiccated and protected from light. Stable for 24 months.
Peer-reviewed references
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
EBioMedicine · 2025
PMID 40609154PubMedEfficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet · 2023
PMID 37364590PubMed
Titles and journals pulled from PubMed and cached for 7 days. Links open in a new tab.